EyePoint Pharmaceuticals: Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD

EyePoint Pharmaceuticals Treating Wet Age-Related Macular Degeneration

In today's press release, EyePoint Pharmaceuticals (EYPT) announced positive topline results of its Phase 2 DAVIO 2 trial of EYP . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.